Samueli Integrative Cancer Pioneering Institute

About

Samueli Integrative Cancer Pioneering Institute

The Samueli Institute was born in 2023 from a rare convergence of bold visions, united by a belief in the power of integrative translational cancer research to inspire hope and save lives.

Our story

The Power of the Nexus

The Institute is anchored within the renowned Davidoff Cancer Center at Rabin Medical Center, pioneering patient-centric care that integrates clinical excellence, advanced therapies and healing.

Supported by the visionary Samueli Foundation, the Institute is uniquely positioned at the nexus of medical innovation and real-world data.

With access to Clalit's rich, multidisciplinary and longitudinal datasets, spanning over 5 million Israelis across community and hospital settings, the institute serves as an impact amplifier for applied cancer research, powering early detection, prediction, and the development of novel treatments through an agile, bedside-to-bench-to-bedside model.

Advancing whole-person health through integrative science, the Institute exemplifies the spirit of Israeli-led medical achievement, realizing the vision of the HealthTech nation advancing global health.

Trailblazing founders

  • Dr. Susan & Dr. Henry Samueli

    Samueli Foundation

  • Prof. Gal Markel

    Founder & Chairman · MD, PhD & MBA

  • Prof. Salomon M. Stemmer

    Co-Founder & Co-Chairman · MD

  • BG (Res.) Avner Paz-Tsuk

    Founding CEO · BSc, MBA

Our scientific fields of impact

Three research hubs

Research Hub

Health Data Analytics

We are hiring

We leverage advanced analytics, AI and ML capabilities to design multilayer and multimodal solutions that drive clinical insights, utilizing our unique access to Clalit's comprehensive birth-to-death datasets. Conducting research at the point-of-care within the Davidoff Cancer Center enables close collaboration between clinical and analytics experts to design and administrate novel treatment protocols.

We focus on unlocking advanced insights from structured and unstructured clinical data to drive novel models for early detection, prediction and prognostication, personalized treatment, and real-time clinical decision support.

This data-powered innovation is redefining the boundaries of cancer research, shaping the future of precision oncology and setting new standards for how cancer is detected, understood and treated.

Led by

Ronen Tal

Chief Data Officer

Seasoned technology leader with 25 years of industry experience spanning data architecture, AI model development and advanced analytics. Enables organizations to harness data for impactful predictions and decision-making.

Building on our key achievements 2023–2025

  • Developed AI-based tools for extracting clinical insights from unstructured medical reports
  • Launched MedScout©, an AI platform optimizing patient recruitment for clinical trials
  • Created CompoCT©, an AI tool that analyzes CT images to automatically determine body composition
  • Designed an ML model for HCC risk prediction in MASLD (fatty liver) patients

Growth strategy »2030

  • Scale up our data assets and analytical capabilities to generate innovative, patient-centric clinical insights
  • Accelerate novel therapeutics R&D through new computational analytics tools
  • Forge new partnerships in Israel and globally to impact cancer patients worldwide
  • Achieve global standing by leading innovation in computational health
3
Strategic partnerships
10
New database layers
20
Clinical insights
10
Publications
6
Strategic grant wins

R&D Hub

NextGen Biology

We advance cutting-edge cell and gene therapies utilizing the patient's own immune cells, to bring new hope and treatment to cancer patients. Our technological and clinical infrastructure powers end-to-end solutions spanning discovery, translational research and development, clinical manufacturing and treatment administration.

Backed by leading immunotherapy experts, a GMP facility and the clinical capabilities of the Davidoff Center, we accelerate promising drug candidates from concept to treatment.

Led by

Prof. Michal Besser, PhD

Chief Technology Officer

Global expert in cell therapy, with 20+ years of experience in academia and industry, including vast expertise in early-stage innovation, translational research, process development and clinical manufacturing. Led 500+ CAR T and TIL in-house produced infusions, published nearly 100 research papers, and advises global biotech firms.

Building on our key achievements 2023–2025

  • Built a state-of-the-art GMP facility at a leading public hospital in less than one year
  • Established SPRINT© submission platform for novel CAR T production in under 90 days per protocol
  • Filed 2 patent applications for novel therapies targeting a broad range of cancer types
  • Discovered a novel immunotherapy, now in translational phase for clinical use
  • Led development and regulatory submission of 3 novel cell & gene therapy protocols within 18 months

Growth strategy »2030

  • Become a center of excellence for next-generation bio therapeutics
  • File broad-ranging patent applications for revolutionary engineered cell therapies
  • Deliver our ground-breaking treatments to hundreds of patients
  • Amplify our impact through a web of strategic partnerships across Israel and globally
7
Novel protocols
6
Patent applications
20
Publications
240
Patients treated

R&D Hub

Integrative Medicine

We are pioneering a new standard of integrative cancer care through cutting-edge clinical research that converges conventional and complementary treatments and approaches. Grounded in whole-person, data-driven and personalized science, our work integrates multimodal interventions and advanced technologies to improve both patient health and well-being.

By measuring objective and subjective health indicators, we generate evidence-based strategies that empower patients, enhance treatment response and close critical research gaps, unlocking transformative health outcomes in oncology and beyond.

Led by

Daphna Murvitz

Chief Integrative Medicine Officer

Seasoned executive and entrepreneurial leader with a track record in cross-disciplinary ecosystem innovation across HealthTech and high-tech. Co-Founder & former CEO of 8400 The Health Network, a national initiative to accelerate Israel's HealthTech ecosystem.

Building on our key achievements 2023–2025

  • Generative AI-Driven Patient Companion: a new standard of care enabling proactive, personalized patient engagement in the cancer healing process
  • Nutrition Intervention: a pioneering multimodal personalized intervention tackling cancer-associated malnutrition
  • Cancer Symptoms Management: an AI tool, based on the biopsychosocial model, to enhance clinical precision, decision-making and patient quality of life
  • Psychoneuroimmunology (PNI) in Cancer Care: exploring personalized XR/neurofeedback to enhance treatment effects

Growth strategy »2030

  • Become a sandbox hub for multimodal, cross-disciplinary cancer research
  • Grow the number of integrative clinical research interventions
  • Drive novel research methodologies that quantify and measure whole person health metrics
  • Advance local and global partnerships and inter-disciplinary collaborations
12
Sandbox projects
5
Clinical research interventions
5
Strategic collaborations
2
Strategic grant wins

Institute-wide

Achievement highlights and growth strategy »2030

Achievement highlights

  • First patients treated within 24 months of initiating GMP lab construction
  • Developed a groundbreaking computational model to predict and detect early-stage malignancy in high-risk groups
  • Launched an integrative research platform to explore the impact of converging conventional, complementary and tech-powered care on patient engagement, outcomes and well-being
  • Filed patents for a novel therapeutic for broad solid malignancy indications, in record time
  • Boosted patient screening for clinical trials via MedScout's big-data analytics of structured and unstructured medical records

Growth strategy »2030

  • Become a globally recognized bio-therapeutics research facility
  • Advance the development and production of next-generation cell & gene therapies
  • Establish global standing by pioneering new methods and tools in computational health
  • Administer a new integrative oncology standard of care
  • Accelerate income generation to fuel and scale up novel research

Powering an end-to-end innovation cycle. Novel translational research, GMP manufacturing standards and data-driven care models continuously inform one another, accelerating therapeutic development and improving health and well-being.

Let's scale the impact together!

We welcome strategic partnerships to redefine the frontier of cancer prevention and care and bring hope to patients worldwide.

See open positionsSamueliInstituteData@clalit.org.il